Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes

Status

Suspended

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00948324

Enrollment

400

Registered

2009-07-29

Start date

2008-06-30

Completion date

2021-12-31

Last updated

2017-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

ype 2 diabetes mellitus, continuous subcutaneous insulin infusion,, α-lipoic acid ,rosiglitazone ,metformin，therapy

Brief summary

The purpose of this study is to investigate and evaluate the effects of different interventions (1.continuous subcutaneous insulin infusion,2.continuous subcutaneous insulin infusion combined with rosiglitazone 3.continuous subcutaneous insulin infusion combined with metformin,4.continuous subcutaneous insulin infusion combined with α- thioctic acid daily injections,) on glycemic control, B-cell function and the remission rate in newly-diagnosed type 2 diabetic patients.

Interventions

DRUGCSII,ALA,MET,RSG

CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

25 Years to 70 Years

Healthy volunteers

Inclusion criteria

* newly diagnosed type 2 diabetes,

Exclusion criteria

* received previous antihyperglycaemic therapy

Design outcomes

Primary

Measure	Time frame
beta cell function;fast blood glucose;	2011/05

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026